{"cluster": 43, "subcluster": 37, "abstract_summ": "In patients without IBD and COVID\u201019, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID\u201019.[2]Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), emerging in Wuhan, China and developing into a pandemic with rapidly emerging cardiovascular manifestations [...].The gastrointestinal tract represents a target organ for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), warranting a thorough discussion on the consequences, particularly regarding inflammatory bowel diseases.Takotsubo syndrome has scarcely been reported in patients with COVID-19, but it is possible that the cytokine storm associated with the infection can trigger Takotsubo syndrome in patients with underlying risk factors for Takotsubo (emotional distress, physical distress, history of psychiatric disorders).We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID\u201019).[1]Cienfuegos et al. have treated several COVID-19 patients with thromboembolic complications, including bowel ischemia.Here, aspects of gastrointestinal involvement with SARS-CoV-2, the role of viruses as modulators of mucosal immunity and as treatment-related safety hazards, and the current clinical evidence will be discussed.The combination of endothelial dysfunction with a generalized inflammatory state and complement elements may together contribute to the overall pro-coagulative state described in COVID-19 patients leading to venular as well as to arteriolar occlusions.", "title_summ": "IBD in the time of corona \u2014 vigilance for immune-mediated diseasesIntra-abdominal hypertension as a trigger of \u201cgut failure\u201d in SARS-CoV-2 infection: effect of open abdomen (OA) and negative pressure therapy (NPT) on respiratory and gastrointestinal (GI) functionA fatal case of COVID-19 due to metabolic acidosis following dysregulate inflammatory response (cytokine storm)Takotsubo cardiomyopathy triggered by SARS-CoV-2 infection in a critically ill patientLetter: intestinal inflammation, COVID\u201019 and gastrointestinal ACE2 \u2013 exploring RAS inhibitorsEndotheliitis and Endothelial Dysfunction in Patients with COVID-19: Its Role in Thrombosis and Adverse Outcomes.Thromboinflammation and the hypercoagulability of COVID-19.Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19.COVID-19 and the Heart.COVID-19 and the endothelium.", "title_abstract_phrases": "Takotsubo syndrome has scarcely been reported in patients with COVID-19, but it is possible that the cytokine storm associated with the infection can trigger Takotsubo syndrome in patients with underlying risk factors for Takotsubo (emotional distress, physical distress, history of psychiatric disorders).Letter: intestinal inflammation, COVID\u201019 and gastrointestinal ACE2 \u2013 exploring RAS inhibitorsWe read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID\u201019).[1]Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), emerging in Wuhan, China and developing into a pandemic with rapidly emerging cardiovascular manifestations [...].IBD in the time of corona \u2014 vigilance for immune-mediated diseasesThe gastrointestinal tract represents a target organ for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), warranting a thorough discussion on the consequences, particularly regarding inflammatory bowel diseases.Intra-abdominal hypertension as a trigger of \u201cgut failure\u201d in SARS-CoV-2 infection: effect of open abdomen (OA) and negative pressure therapy (NPT) on respiratory and gastrointestinal (GI) functionCOVID-19 gastrointestinal manifestations could be attributed to SARS-CoV-2-induced small vessel thrombosis.While many people with COVID-19 develop mild to moderate symptoms, some develop profound seemingly unchecked inflammatory responses leading to acute lung injury and hypoxemic respiratory failure, the most common cause for death.Cienfuegos et al. have treated several COVID-19 patients with thromboembolic complications, including bowel ischemia."}